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Background: The prognostic value of biochemical tests in critically ill patients with multiple organ failure and
suspected bowel ischemia is unknown.
Methods: In a prospective observational cohort study intensive care patients were included when the attending
intensivist considered intestinal ischemia in the diagnostic workup at any time during intensive care stay. Patients
were only included once. When enrolment was ended each patient was classified as ‘proven intestinal ischemia’,
‘ischemia likely’, ‘ischemia unlikely’ or ‘no intestinal ischemia’. Proven intestinal ischemia was defined as the gross
disturbance of blood flow in the bowel, regardless of extent and grade. Classification was based on reports from the
operating surgeon, pathology department, endoscopy reports and CT-scan. Lactate dehydrogenase (LDH), creatine
kinase (CK), alanine aminotransferase (ALAT), L-lactate were available for the attending physician. D-lactate and intestinal
fatty acid binding protein (I-FABP) were analysed later in a batch. I-FABP was only measured in patients with proven
ischemia or no ischemia.
Results: For 44 of the 120 included patients definite diagnostic studies were available. 23/44 patients (52%) had
proven intestinal ischemia as confirmed by surgery, colonoscopy, autopsy and/or histopathological findings. LDH in
these patients was 285 U/l (217–785) vs 287 U/l (189–836) in no-ischemia; p = 0.72. CK was 226 U/l in patients with
proven ischemia (126–2145) vs 347 U/l (50–1427), p = 0.88. ALAT was 53 U/l (18–300) vs 34 U/l (14–34), p-0,56. D-lactate
0.41 mmol/l (0.11-0.75) vs 0.56 mmol/l (0.27-0.77), p = 0.46. L-lactate 3.5 mmol/l (2.2-8.4) vs 2.6 mmol/l (1.7-3.9), p = 0.09.
I-FABP 2872 pg/ml (229–4340) vs 1020 pg/ml (239–5324), p = 0.98. Patient groups proven and likely ischemia together
compared to unlikely and no-ischemia together showed significant higher L-lactate (p = 0.001) and higher
D-lactate (p = 0.003).
Conclusions: Measurement of LDH, CK, and ALAT did not discriminate critically ill patients with proven intestinal
ischemia from those with definite diagnosis no-ischemia. However, L-lactate and D-lactate levels were higher in patients
with proven or likely ischemia and need further study just as I-FABP.
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Critically ill patients occasionally develop ischemia in
the splanchnic region. The incidence of clinically rele-
vant ischemia is only known in cardiac surgery patients
[1,2]. The aetiology is diverse but usually mesenteric is-
chemia is categorized as obstructive or non-obstructive
ischemia. The obstructive form is caused by a thrombus
or embolus in one of the mesenteric arteries or veins.
The non-occlusive mesenteric ischemia (NOMI) develops
due to low flow, usually as a result of severe shock [3]. An
ischemic bowel may also develop after aortic surgery due
to either thrombi or low flow state. In all cases, both the
small and the large bowel may be affected. Whatever the
aetiology, it is difficult to diagnose intestinal ischemia be-
cause of the non-specific clinical signs [4]. Biochemical
markers are often used in the diagnostic workup. The use
of L-lactate is ubiquitous despite its low sensitivity and
specificity [5]. D-lactate, the stereoisomer of the human L-
lactate, may be a more specific marker [6,7]. D-lactate is
strictly a product of bacterial fermentation in the gastro-
intestinal tract including Escherichia coli, Lactobacillus
species, Klebsiella, and Bacteriodes species [7]. During in-
testinal ischemia permeability increases due to decreased
mucosal integrity and D-lactate may diffuse into the portal
circulation [6,7]. It has been shown that serum D-lactate
levels may be an early indicator for the detection of intes-
tinal ischemia [7,8]. A study by Assadian et al. showed
elevated D-lactate levels in patients with histologically
proven ischemic colitis after open aortic reconstruction.
More recently, intestinal fatty acid binding protein I-
FABP, has gained attention. I-FABP is a small (15-kD) pro-
tein within the cytoplasm of mature enterocytes located at
the tips of the villi of the small bowel [9]. The concentra-
tion is undetectable in normal situations [10-13]. Ischemic
damage of the villi leads to release of this protein into the
circulation. It has therefore been promoted as a promising
new serological marker for intestinal ischemia in animals
[11,14,15] and humans [16-18].
Prospective studies to the diagnostic value of these
serum markers in the specific setting of the intensive
care are absent. Hence, the present study is performed
to test the prognostic value of biochemical tests in critic-
ally ill patients with multiple organ failure and suspected
bowel ischemia.
Methods
Study objective and design
The objective of this prospective observational cohort
study is to determine the predictive value of D-lactate,
I-FABP and other more common serological markers of
ischemia (L-lactate, lactate dehydrogenase (LDH), creat-
ine kinase (CK) and alanine aminotransferase (ALAT))
in intensive care patients suspected to have intestinal is-
chemia. The results of L-lactate, LDH, CK and ALATwere readily available for the attending clinician. D-
lactate and I-FABP were stored and measured later in
one batch at the end of the study. D-lactate levels were
additionally measured in a group of healthy volunteers
to determine reference levels. At the start, this study did
not fall under the Dutch research legislation (WMO) be-
cause of its observational character, despite the blood
sampling. In virtually all patients a blood sample drawn
for other measurements could be used for this study,
which limited the number of extra blood sampling. An
informal consultation of the local ethic and scientific re-
view board (Medical Ethical Committee on research, Onze
Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands)
was performed confirming that at that time informed con-
sent was not needed. However, the Dutch ethical commit-
tee on research (CCMO) changed their policy concerning
blood sampling in 2013, after completion of the study.
Setting
The ICU where the study was performed is a closed for-
mat highest-level mixed medical, surgical and cardiac
surgery department with 20 beds in a teaching hospital.
Patients and sample collection
Over a 24-month period intensive care patients were in-
cluded when the attending intensivist considered intestinal
ischemia in the diagnostic workup. This consideration
may have risen on admission or at any moment during in-
tensive care stay. Intestinal ischemia was considered when
physical examination and observation of bowel function
might be congruent with ischemia. Exclusion criteria other
than age below 18 were not defined. As soon as the con-
sideration of intestinal ischemia was raised, a single blood
sample of 4 ml was taken to determine serological data.
From each patient only the first blood sample was
used in the analysis. Repeated samples were excluded.
Data collection
Baseline data of all admitted patients in the ICU are re-
corded in a structured and uniform way in the Patient
Data Management System (Metavision®, Tel Aviv, Israel).
Data from included patients were retrieved from this
database including sex, age, the diagnosis at admission,
mortality at the ICU and severity of illness. The Acute
Physiologic and Chronic Health Evaluation (APACHE)
IV and SOFA scores determined illness severity. Validated
data from pathological studies, endoscopy, radiological
studies and laparotomies were collected from the hospital
information system xCare® (McKesson, Nieuwegein, The
Netherlands).
Patient classification
Patients were classified as ‘proven intestinal ischemia’,
‘ischemia likely’, ‘ischemia unlikely’ or ‘no intestinal
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operating surgeon, pathology department, endoscopy re-
ports and CT-scan. All available study results were inde-
pendently analysed by 2 researchers (B.W and P.V.) and
categorization was made without prior knowledge of
serological markers including plasma D-lactate and I-
FABP levels. In case of disagreement between the two
researchers consensus was reached by reviewing the data
together. Proven intestinal ischemia was defined as the
gross disturbance of blood flow in the bowel, regardless
of extent and grade. Terms used by pathologist or sur-
geon like ‘necrotic changes’, ‘ischemic colitis’, ‘transmural
ischemia’, ‘ischemic changes in the resected tissue’, were
considered decisive.Blood samples
Lactate dehydrogenase (LDH), creatine kinase (CK),
alanine aminotransferase (ALAT) and L-lactate were
analysed according to instructions of the manufacturer
(Roche diagnostics systems, Basel, Switzerland).
The remaining blood of the blood samples were stored
in −80°C and analysed for D-lactate and I-FABP in one
run after closure of the study inclusion.
D-lactate concentration was spectrophotometrically mea-
sured in heparin-plasma. To this end, heparinized blood
was centrifuged at 3200 rpm for 10 min in a clinical centri-
fuge. 500 μL of plasma was deproteinized with 50 μL per-
chloric acid, mixed on a Vortex for 20 s, and kept on ice
for 10 min. Next, the denatured protein solution was
centrifuged at 3200 rpm for 10 min. To 350 μL of the
supernatant 20 μL KOH was added, mixed for 20 s and
kept on ice for 10 min. After centrifugation for 10 min the
neutralized-protein-free plasma (NPFP) was used for ana-
lysis according to Herrera and co-workers [19]. In brief, D-
lactate is oxidized to pyruvate by NAD+ in the presence of
the D-lactate dehydrogenase. Then pyruvate is enzymati-
cally converted by D-alanine aminotransferase (D-ALT) to
D-alanine and 2-oxoglutarate. The latter reaction shifts the
equilibrium to the formation of NADH. The amount of
NADH formed during the reaction is stoichiometric to
the amount of D-lactate in the sample, and it is mea-
sured by the increase in absorbance at 340 nm.
The assay mixture contained, in a final volume of
1000 μL: 111 mmol/L glycylglycine pH 10.0, 111 mmol/L
glutamate, 4.65 mmol/L NAD+, 11.6 U/mL D-alanine
aminotransferase and 50 μL heparin-plasma. After a pre-
incubation of 30 s, the reaction was started by addition of
D-LDH. The production of NADH was followed in time
(10s, 100 s and 200 s) on a Shimadzu spectrophotometer
at 340 nm using a molar extinction coefficient of
6300 L/mol/cm. A sample blank to correct the non-
specific NAD+ transformation was processed using the
same analytical conditions as for the analysis of D-lactate but without adding the enzyme D-LDH and was
subtracted on all samples.
Literature has shown that D-lactate concentrations will
decrease with increasing activities of L-LDH. Indeed, an
activity of LDH greater than 1500 IU/L will result in a
more than 10% deviation. Hence, in plasma of patients
with an LDH activity >1500 the LDH was removed. A
reagent blank to compensate for the small, but continu-
ous, non-enzymatic transformation of NAD+at alkaline
pH was performed in every run and was subtracted from
the calibrators, QCs and samples.
Intestinal fatty acid binding protein (I-FABP) was
measured in plasma using a commercially available
enzyme-linked immunosorbent assay (ELISA) (Hycult
Biotechnology b.v., Uden, The Netherlands). The wells
of the EIA plate were coated with the monospecific
polyclonal antibody (10 μg/ml). First, the samples were
diluted twice. To this end, 150 μL diluent buffer was
added to 150 μL sample. Next, 100 μL of the standard
solution and 100 μL of the diluted sample were added
to the plate and incubated for 60 min at 20 C. This was
done in duplo. After incubation, 100 μL of the conjugate
tracer was added and incubated for 60 min. Next 100 μL
of the conjugate Streptavidin-peroxidase was added and
incubated for another 60 min. The wells were washed
three times with washing buffer (10 mL washing buffer
with 390 mL aqua mill) after each incubation. Finally,
the reaction was started by adding 100 μL of the tetra-
methylbenzidine (TMB) substrate (x) every 15 sec to
each strip and incubated for another 20 min, and
stopped by the addition of citric acid (x) every 15 sec to
each strip (and mixed between). The absorbance at
450 nm was measured spectrophotometrically. A stand-
ard curve is obtained by plotting the absorbance (linear)
versus the corresponding concentrations of the human
I-FABP standards (log). The human I-FABP concentra-
tions of samples, which are run concurrently with the
standards, were determined from the standard curve.
Statistical analysis
Continuous variables such as CK, LDH, ALAT, I-FABP,
D-lactate and L-lactate were expressed as median and
interquartile range (IQR) because of their skewed distribu-
tion. The comparison of groups was performed with the
Mann–Whitney U-test or the Kruskal-Wallis test were ap-
propriate. Data is shown as absolute numbers and percent-
age (%). Differences in proportions were evaluated using
the Fisher exact test for nominal variables. Sensitivity, spe-
cificity, positive predictive value and negative predictive
value were calculated according to standard methods. ROC
analysis with 95% confidence interval (CI) was performed
for the best performing marker, L-lactate, with a positive
diagnosis of ischemia tested against the L-lactate level.
P-values less than 0.05 were considered statistically
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tical software SPSS version 18.0 (SPSS Inc, Chicago,
Illinois, USA).Results
Patients
The study was performed over a period of 24 months. In
the study period 2988 patients were admitted to the
ICU. 138 samples were collected. 18 samples were dupli-
cate samples of the same patient and therefore excluded
for analysis. Baseline characteristics of the 120 included
patients are shown in Table 1. The most common diagno-
sis on admission (39%) in patients with proven intestinal
ischemia was other surgery, which included intra-thoracic
vascular and heart valve surgery.
Figure 1 shows the flow chart for included patients.
For 44 of the 120 included patients definite diagnostic
studies were available. For the other 76 patients a defin-
ite diagnosis could not be made. For the 44 patients with
a definite diagnosis, 23 patients (52%) had the diagnosis
bowel ischemia confirmed by surgery (n = 20), colonos-
copy (n = 2), CT scan (n = 1), autopsy (n = 3) and/or
histopathological findings (n = 10). The other 21 patients
(48%) underwent surgery (n = 17) and/or autopsy (n = 5)
but did not have signs of intestinal ischemia.
20 patients with intestinal ischemia underwent laparot-
omy, which confirmed ischemia and underwent subse-
quent surgical resection (87%), while 17 patients without
intestinal ischemia also had abdominal surgery (76%).D-lactate
D-lactate levels were measured in all patients and in





Age (years) 73 (64.0 – 78.0) 67 (63 –
Male 9 (43) 11 (69)
APACHE IV predicted mortality 0.49 (0,26-0.73) 0.42 (0.1
Diagnosis on admission (%)
Severe sepsis & septic shock 5 (21.7) 2 (12.5)
Cardiogenic shock 1 (4.3) 1 (6.3)
Hypovolemic shock 1 (4.3) 3 (19)
After CPR - -
Aortic aneurysm repair 3 (13) 5 (31.3)
After other surgery 9 (39) 4 (25)
Other 4 (17.4) 1 (6.3)
Mortality 13 (57) 4 (25)
All values are medians and interquartile ranges or absolute number with (%).
*p-value of ‘Proven intestinal ischemia’ compared to ‘No intestinal ischemia’.Figure 2. A significant difference between healthy con-
trols and patients with proven or no intestinal ischemia
was found (p = 0.023 and p = 0.001, respectively). How-
ever, there was no difference between patients with
proven compared to no intestinal ischemia (p = 0.46).
When all groups were taken into account, no statistical
difference was found between groups (p = 0.099). The
combined group proven and likely ischemia together
compared to unlikely and no-ischemia together showed
D-lactate levels of 0.79 (IQR 0.49-1.16) versus 0.65 (IQR
0.37-0.94); p = 0.003.I-FABP
I-FABP was only measured in the groups proven and no
intestinal ischemia. Patients with intestinal ischemia
(Figure 2) showed a non-significantly higher median I-
FABP level compared to those without intestinal ischemia
(2872 vs 1020 pg/ml, p = 0.98).CK, LDH and ALAT
ALAT, CK and LDH levels were measured in all patients
and data is shown in Table 2 and Figure 3. No significant
differences were shown between separate groups. When
all groups were taken into account, no statistical differ-
ence was found between groups (p = 0.43 for ALAT, p =
0.53 for CK and p = 0.20 for LDH). The combined
groups proven and likely ischemia together compared to
unlikely and no-ischemia together showed CK levels of
258 (IQR 156–1024) versus 562 (IQR 129–1686); p = 0.51.
The combined groups proven and likely ischemia together
compared to unlikely and no-ischemia together showed
LDH levels of 350 (IQR 225–785) versus 399 (IQR





77) 69 (61 – 77) 70.0 (62.0 – 77.5) 0.56
25 (42) 14 (67) 0.08
3 – 0.79) 0.45 (0.24 – 0.73) 0.45 (0.27 – 0.61) 0.53
7 (11.7) 9 (42.6)
7 (11.7) 1 (4.8)
2 (3.3) -
12 (20) 1 (4.8)
8 (13.3) 3 (13)
11 (18.3) 5 (23.8)
13 (21.7) 2 (9.5)
15 (25) 7 (33) 0.14
Figure 1 Flowchart of included patients.
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ischemia together showed ALAT levels of 61 (IQR 18–390)
versus 70 (IQR 25–204); p = 0.77.
L-lactate
When all groups were taken into account, a statistical sig-
nificant difference was found between groups (p = 0.001).
However, between individual groups a statistical sig-
nificant difference was present only in the comparison
between ischemia likely and unlikely (p = 0.002). The
median L-lactate levels in patients with proven and no
ischemia were 3.5 mmol/L (2.2-8.4) and 2.6 mmol/L
(1.7-3.9), respectively (p = 0.09). The combined groups
proven and likely together compared to unlikely and no-
ischemia together showed L-lactate levels of 3.9 (IQR
2.4-7.4) versus 1.9 (IQR 1.3-3.2); p = 0.001.
We determined the best cut-off point to differentiate
patients with proven ischemia and no intestinal ischemia
by using the sum of maximum sensitivity and specificity.
In a ROC-analysis (Figure 4) showed an area under
curve of 0.65 (95%CI 0.49-0.81, p = 0.09). Using a cut-off
point of 2.2 mmol/L the sensitivity was 78% and the
specificity was 48%.
Discussion
The diagnostic process concerning intestinal ischemic in
critically ill patients on the intensive care unit is challen-
ging. The present study of prospectively collected biochem-
ical markers shows that these data would, in retrospect, not
have helped the clinician to make the diagnosis more easily
when only patients with proven ischemia and no ischemiawere taken into account. The most common biochemical
marker, L-lactate, was in general higher in patients with
compared to patients without a definite diagnosis of intes-
tinal ischemia but it could not discriminate between these
patients sufficiently in the clinical setting. Combined group
of proven and likely ischemia did show higher L-lactate
compared to patients unlikely or no ischemia. Unsuccessful
discrimination was the case for creatine kinase, lactate de-
hydrogenase and ALAT. In addition, we studied D-lactate
and I-FABP as they were recently linked to high diagnostic
accuracy in patients in the emergency ward and in-hospital
[6,20,21]. D-lactate is exclusively produced by the indigen-
ous bowel flora. An ischemic mucosa may lead to trans-
location of D-lactate that can be measured in plasma.
Indeed, compared to healthy controls, D-lactate levels were
elevated. However, in critically ill patients with and without
proven intestinal ischemia serum D-lactate levels were
equally elevated but the combined group proven and likely
ischemia had a significantly higher D-lactate. I-FABP has
recently become available and is specifically released by is-
chemic mucosa. The range of I-FABP levels was broad in
patients with and without definite bowel ischemia. As renal
function has not been proven to be a factor determining
the level of these biomarkers we did not take this into
account.
Clinical symptoms have a low diagnostic power to de-
tect NOMI [4]. In the intensive care setting symptoms
like inability of enteral feeding may suggest an ischemic
bowel but often occur in the absence of ischemia as well
and there is a lack of relevant clinical studies in the crit-
ically ill. In additional to clinical symptoms, now the












D-lactate (mmol/l) 0.41 (0.11 – 0.75) 0.54 (0.34-0.90) 0.33 (0.08-0.62) 0.56 (0.27 – 0.77) 0.20 (0.038 – 0.33) 0.003 0.46
I-FABP (pg/ml) 2872 (229–4340) Not available Not available 1020 (239–5324) Not available Not available 0.98
L-lactate (mmol/L) 3.5 (2.2 – 8.4) 4.1 (2.8-6.7) 1.8 (1.2-3.0)# 2.6 (1.7 – 3.9) Not available 0.001 0.09
ALAT (U/I) 53 (18 – 390) 67 (20–637) 79 (33–204) 34 (14 – 34) Not available 0.77 0.56
CK (U/I) 226 (126 – 2145) 430 (169–992) 631 (161–1699) 347 (50 – 1427) Not available 0.51 0.88
LDH (U/I) 285 (217 – 785) 366 (250–1586) 435 (282–752) 287 (189 – 836) Not available 0.52 0.72
All values are medians and interquartile ranges. *p-value represents proven compared to no intestinal ischemia. #p = 0.002 for ischemia likely vs unlikely. $p-value represents proven and likely together compared to




















Figure 2 Boxplots of I-FABP and D-lactate in patients with and
without intestinal ischemia.
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power in the diagnostic process of intestinal ischemia as
well. This may be explained by several reasons. First, the
test characteristics of a diagnostic test are determined by
the population were it is tested. Most serological tests
that are used in the intensive care have been developed
for in-hospital patients in general or specific populations
(for instance patients after vascular surgery) and have
not been tested in critically ill patients in particular. The
present cohort of patients was even a subset of critically
ill patients as they were selected for their suspected
splanchnic ischemia. The severity of illness, illustrated
by the APACHE IV system, is high. In this specific popu-
lation marginal splanchnic perfusion might be highly
prevalent, which is suggested by the high L-lactate and
the high I-FABP in all patients. For the same reason, the
results of the present study cannot be extrapolated to
non-critically ill patients. Second, it is likely that some
patients in whom a definite diagnosis could not be made
did have intestinal ischemia. The sample size of this
study is relatively small and it might be argued that a lar-
ger trial is still needed to determine the exact value ofthe biochemical markers, which may be particularly true
for L-lactate, D-lactate and I-FABP.
Our results match with the study from Block et al.
[22] although their population was different. They found
that in patients who presented with an acute abdomen,
lactate and I-FABP did not discriminate between ische-
mia or no ischemia. The majority of their patients had
obstructive mesenteric ischemia where most critically ill
patients have NOMI due to low flow. Block et al. found
D-dimer discriminating for ischemia [22]. As most of
critically ill patients with organ failure and central lines
have an increased D-dimer, we did not take that into
account. Poeze et al. [6] studied D-lactate in patients
after aortic aneurysm repair with and without ischemic
complications. D-lactate discriminated adequately be-
tween these two groups. We could not confirm this
finding as in our subsets of patients with aortic
aneurysm repair a significant difference in any of the
markers was not present. Assadian et al., in concord-
ance with our study, did not find different D-lactate
levels in ischemic patients compared to non-ischemic
patients [8]. Collange et al. could not find an elevated
D-lactate level perioperative [23]. Thuijls et al. found in
a study in emergency room and in-hospital patients
with acute abdomen and suspected for intestinal ische-
mia that plasma I-FABP was significantly higher in
patients with ischemia compared to patients without is-
chemia [20]. In our patient population of critically ill
patients this was not the case. It is likely to be ex-
plained by the mucosal ischemia, which is highly preva-
lent in severely ill patients. In addition, we did not
measure I-FABP in the likely and unlikely groups. The
same group of researchers found for I-FABP a sensitiv-
ity of 100% and a specificity of 98% for patients who
developed intestinal necrosis after aortic surgery [21].
In our subset of patients we could not confirm this
finding. There is some discussion concerning the use of
the different I-FABP ELISA in humans but it remains
speculative what the results would have been when
using a different test [24].
Several limitations of the study need discussion. A
‘golden standard’ for the diagnosis of bowel ischemia is
lacking for 76 out of 120 patients. An unknown propor-
tion of these patients will have suffered from an ische-
mic bowel. However, these patients did not have surgery
or autopsy to confirm the diagnosis. As a consequence,
bias may have occurred. In addition, some patients may
have had temporarily ischemia, which resolved without
surgery. There is an interaction between mortality and
the categorization of patients. Bowel ischemia is associ-
ated with a higher mortality, which may lead to autopsy
and autopsy is a major tool to detect proven ischemia.
As a result, autopsy has predominantly been performed
in patients with definite ischemia or no ischemia. The
Figure 3 Boxplots of L-lactate, CK, LDH and ALAT in patients with and without intestinal ischemia.
Figure 4 ROC curve of L-lactate to detect intestinal ischemia.
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lower (Table 2) and, as a consequence, autopsy is less
frequently performed. When we combine proven and
likely ischemia and compare this new group with a com-
bined group unlikely and no ischemia then L-lactate and
D-lactate were significantly different between these two
groups (Table 2). Some of these patients probably had
temporarily ischemia but did not die because of an is-
chemic bowel and autopsy did not take place. Above
considerations make clear that, unavoidably, the study
suffers from some extend of selection as only 44 patients
had a definite diagnosis. Nevertheless, this study is the
first and largest that determined in a clinical setting the
usefulness of biochemical markers in the diagnostic
process of intestinal ischemia. We conclude that it is
unlikely that biochemical results of, CK, LDH, and
ALAT can lead the physician in clinical decision making
concerning critically ill patients with suspected intestinal
ischemia. For L-lactate, D-lactate and I-FABP more stud-
ies are needed.
Conclusion
It is unlikely that biochemical results of, CK, LDH, and
ALAT can lead the physician in clinical decision making
concerning critically ill patients with suspected intestinal
ischemia. For L-lactate, D-lactate and I-FABP more studies
are needed.
Key messages
• Intestinal ischemia in the critically ill patient is diffi-
cult to diagnose
• Biochemical tests are frequently used in the diagnos-
tic workup in patients with suspected intestinal
ischemia
• A L-lactate serum level of 2.2 mmol/l shows a sensitiv-
ity of 78% and specificity of 48% and a ROC value of
0.65
• LDH, ALAT and CK could not discriminate between
patient with and without an ischemic bowel
• The specific markers L-lactate, D-lactate and I-FABP
may be useful in case of intestinal ischemia in critically
ill patients but more studies are needed.
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